1 Electrocardiograph (ECG) Policy Version: 1 January 2017
SH CP 204
Electrocardiograph (ECG) Policy
Version: 1
Summary:
The aim of the ECG policy is to provide pragmatic advice as to what is best practice and inform clinicians of potential cardiac risks to patients treated in mental health services.
Keywords (minimum of 5): (To assist policy search engine)
Medication, Effects, Cardiovascular, Physical, Health, ECG, Electrocardiogram, HDAT
Target Audience:
All Clinical/Social Care Staff
Next Review Date: September 2018
Approved and Ratified by:
Medicines Management Committee
Date of meeting: 16 November 2016
Date issued:
January 2017
Author:
Juliet Wells, Principal Pharmacist
Sponsor:
Mayura Deshpande, Clinical Service Director, Adult MH
2 Electrocardiograph (ECG) Policy Version: 1 January 2017
Version Control
Change Record
Date Author Version Page Reason for Change
2014 Juliet Wells 1 All Review and transferred to SHFT format
2014 Tim Coupland, Dr Raja Badrakalimuthu Dr Daniel Pearce Dr Amanda Taylor,
1 All “
2016 Steve Coopey 1 All Reviewed, TNA completed
2016 Ricky Somal 1 All Reviewed EqIA completed
2016 Juliet Wells 1 Medicines update
2016 Francis Johnson, Deputy Chief Pharmacist
1 Amendments following MMC
9/1/18 Review date extended from Jan to March 2018
23/3/18 Review date extended to July 2018
23/3/18 Review date extended to Sept 2018
Reviewers/contributors
Name Position Version Reviewed &
Date
Medical Advisory Committee V1 2014
Medicines Management Committee V1 2014
Medicines Committee Management V1 2016
Rebecca Henry V1 2016
3 Electrocardiograph (ECG) Policy Version: 1 January 2017
CONTENTS
Page
1. Introduction 4 2. Background 4 3. Procedure 5 4. Training 8 5. Important Note 8 6. Monitoring 9 7. Associated documents 9 Appendices
A1 Psychotropic medication effects on QTc interval 10 A2 ECG Fax Back Service form 12 A3 ECG Fax Back Service 13 A4 ECG Easy Guide 15 A5 Training Needs Analysis (TNA) 16 A6 Equality Impact Assessment (EqIA) 17
4 Electrocardiograph (ECG) Policy Version: 1 January 2017
ECG Policy 1. INTRODUCTION 1.1 The aim of the ECG policy is to provide pragmatic advice as to what is best
practice and inform clinicians of potential cardiac risks to patients treated in mental health services.
2. BACKGROUND 2.1 Increasingly there is recognition of the cardiotoxic effects of psychotropic
medication as well as the effect of physical intervention such as restraint. This is a summary of the information available and some of the factors that increase cardiac risks:
i) The drug factors ii) Patients factors that increase cardiac risk
2.2 Drug Factors: 2.2.1 QTc effects
Many psychotropic drugs are associated with ECG changes and it is possible that certain drugs are causally linked to serious ventricular arrhythmias and sudden cardiac death. Some antipsychotic drugs block cardiac potassium channels and are linked to prolongation of the QT interval which is a risk factor for ventricular arrhythmias which are occasionally fatal. Tricyclics antidepressants are sodium channel antagonists which prolong QRS and QT interval effects. These are usually evident only following overdose (see Appendix 1). Concurrent use of more than one QTc prolonging drug
2.2.2 Metabolic Inhibition
The effect of drugs on the QTc interval is usually plasma level dependent (i.e. dose) and drug interactions are therefore important, especially when metabolic inhibition results in increased plasma levels of the drug affecting QTc. Examples of metabolic inhibitors are : - Fluvoxamine, Fluoxetine, Paroxetine and Valproate.
2.2.3 Other Cardiac Effects Clozapine is associated with tachycardia, myocarditis, cardiomyopathy and atrial fibrillation (AF). Olanzapine, Paliperidone & Tricyclic antidepressants are associated with AF. Anticholinergics are associated with tachycardia. Acetylcholinesterase inhibitors used in management of dementia are associated with bradycardia and asystole. Also consider concurrent diuretic therapy and digoxin
5 Electrocardiograph (ECG) Policy Version: 1 January 2017
2.3 Patient Factors: 2.3.1 Physiological risk factors for QTc prolongation and arrhythmia
These include pre-existing cardiac disease, long QT syndrome, bradycardia, ischemic heart disease, myocarditis, myocardial infarction, left ventricular hypertrophy, recent cardioversion with QT prolonging drug, metabolic causes, hypokalaemia, hypomagnesaemia, hypocalcaemia, extreme physical exertion, stress or shock, genetic predisposition, anorexia nervosa, malnourishment, extremes of age i.e. children or elderly and female gender, renal or hepatic impairment.
2.3.2 Patient cardio vascular risk factors:
With respect to cardio vascular disease, other risk factors are: smoking, elevated lipids, family history of heart disease/QTc prolongation, obesity and life style issues. Obesity and impaired glucose tolerance represent a much greater risk to patient morbidity and mortality than the uncertain outcome of QTc changes.
2.3.3 Behaviours responsible for increased risks:
Restraint and rapid tranquillisation of patients, and particularly the use of high dose antipsychotics, are associated with increased cardiac risk factors.
A history of illicit drug use, may compound the risks due to possible increased heart rate, exhaustion, hypotension and excitement. Patients on drugs such as methadone and cocaine which are associated with cardiogenic effects are recommended to have ECG at baseline.
3. PROCEDURES 3.1 Which patients require an ECG? 3.1.1 Before starting any psychotropic medications an electrocardiogram (ECG) should be offered if:
specified in the summary of product characteristics (SPC)
physical examination shows specific cardiovascular risk (such as diagnosis of high blood pressure)
there is personal history of cardiovascular disease, or
the service user is being admitted as an inpatient
or indicated in physical health monitoring guideline
3.1.2 For patients on high dose antipsychotics or antipsychotics such as Clozapine and Pimozide with high risk of cardiotoxicity regular ECG monitoring will be required. Regular monitoring may be required for patients on specific antidepressants such as Citalopram and high dose venlafaxine. Please refer to physical health monitoring guide for frequency of ECG monitoring.
6 Electrocardiograph (ECG) Policy Version: 1 January 2017
Indications for ECG Monitoring
Psychotropic medication ECG Monitoring
Acetylcholinesterase inhibitors (APT,2007, 13, 178-184)
Baseline : If pulse > 60 bpm but with history of falls, syncopal attacks, on cardiovascular medications for rate/ rhythm control or with significant cardiovascular illness or if pulse <60 bpm 1
Citalopram & Escitalopram (Applies to patients with cardiac disease; MHRA, Dec 2011)
Baseline Citalopram: Every 6 months if dose greater than 40mg/day (or if dose greater than 20mg/day in patients 65 years of age or more) Escitalopram: Every 6 months if dose greater than 10mg/day in patients 65 years of age or more
Lithium (NPSA, 2009)
If there is a risk factor for, or existing, cardiovascular disease, an electrocardiogram is normally performed before treatment begins3.
Haloperidol Baseline is recommended prior to treatment in all patients, especially in the elderly and patients with a positive personal or family history of cardiac disease or abnormal findings on cardiac clinical examination
High dose antipsychotics (NICE) (HDAT)
Baseline, when steady state is reached, 6 monthly, after dose changes or change to other medications which can impact on QTc interval or if clinically indicated.
Clozapine (NICE) Baseline, if clinically indicated or change to other medications which can impact on QTc interval
Tricyclics Baseline If clinically indicated in patients with risk of cardiac arrhythmias.
Methadone All patients should be evaluated for the presence of risk factors for QT prolongation prior to initiating methadone treatment. If risk factors present, baseline ECG is required. ECG monitoring should be considered for methadone doses >150mg/day and in patients with risk factors for QT prolongation, or symptoms that may be attributable to arrhythmia
3.1.3 If an ECG cannot be carried out because of a patient’s mental state or behaviour
(e.g. on admission to an inpatient unit) then this fact and the reasons, must be recorded in the primary case record. An ECG should be done as soon as it is
7 Electrocardiograph (ECG) Policy Version: 1 January 2017
practical. An ECG should be carried out once the medication dose has been stabilised.
3.1.4 All patients over 45 years old or all patients with a history of cardiac problems or
cardiac risk factors should have an ECG prior to ECT. Please refer to the ECT policy (CP69.1) on the Trust Website.
3.1.5 All patients prescribed two or more medications which impact on QTc interval or
associated with arrhythmias should have ECG as recommended by the Physical Health Monitoring Policy of Southern Health NHS Foundation Trust.
3.1.6 Routine baseline ECG may not be required when medications such as Citalopram
or Risperidone is used in small doses and for a short duration in managing behavioural and psychological symptoms of dementia.
3.2 Equipment 3.2.1 Each inpatient unit should have an ECG machine which should be kept in good
working order
3.2.2 The preferred ECG machine for use within Southern Health NHS Foundation Trust is GE MAC 1200ST with interpretation module. When an ECG machine requires replacement this should be the preferred model of choice.
3.2.3 It is the responsibility of the Modern Matron in each in-patient unit to ensure the
functioning and maintenance of the ECG machine. 3.3 Inpatient Services 3.3.1 Each inpatient unit must have an understanding about who does the ECG, how it
is interpreted and when to refer to for specialist opinions. These arrangements will be agreed at a local level.
3.3.2 All inpatient services have to access a Fax Back service for cardiology opinions from Portsmouth Hospital Trust. The request sheet should be completed for all requests (appendix 2 & 3). However, some inpatient units may have arrangements with their local cardiology teams and with whom they can agree appropriate referral criteria.
3.3.3 Modern Matrons (or equivalent) are responsible for ensuring all clinical staff know
the local procedures for arranging ECGs. 3.4 Outpatient Requirements 3.4.1 In general the GP will be responsible for prescribing medication and therefore
also the appropriate monitoring. However, whenever a psychiatrist recommends any medication, they should inform the GP of the monitoring requirements.
3.4.2 If the psychiatrist retains responsibility for prescribing, they are also responsible
for ensuring that the drug monitoring requirements, including ECG, are met e.g. in the case of Clozapine, HDAT or depot medication.
3.4.3 Local arrangements will need to be made concerning how the ECG is obtained
i.e. through the GP or local general hospital. ECG results must be recorded in the appropriate place in the care record and the GP informed.
8 Electrocardiograph (ECG) Policy Version: 1 January 2017
3.4.4 ECGs should be included as part of the Care Planning process with reference to the physical health shared care guidelines.
3.5 Practice 3.5.1 See Appendix 4 for flow chart. 3.5.2 Once the ECG has been carried out the following guidelines for referral should be
followed:
QTc <440 ms (men) or <470 ms (women) No action required unless abnormal T-wave morphology – consider referral to
cardiologist if in doubt.
QTc ≥440 ms (men) or ≥470 ms (women) but <500 ms Consider reducing dose or switching to drug of lower effect; repeat ECG and
consider referral to cardiologist.
QTc ≥500 ms Stop suspected causative drug(s) and switch to drug of lower effect; refer to
cardiologist immediately.
Abnormal T-wave morphology Review treatment. Consider reducing dose or switching to drug of lower
effect. Refer to cardiologist immediately.
3.5.3 For patients with dementia considered for Acetylcholinesterase inhibitors:
If HR more than 50 bpm but associated with syncope, falls or symptoms of bradycardia, then withhold/ stop drug and seek specialist/ GP advice for underlying cause; if cause is unrelated to drug or patient is fitted with pacemaker consider retrial of drug and check pulse after a week.
If HR less than 50 bpm then withhold/ stop drug and seek specialist/ GP advice for underlying cause; if cause is unrelated to drug or patient is fitted with pacemaker consider retrial of drug
4. TRAINING 4.1 Each Area/Service must organise training for staff to ensure that:
i) Adequate numbers of nurses (band 5 and above) and doctors in every team
are trained in use of ECG machine and in interpreting ECG. ii) Doctors should also familiarise themselves with the process involved seeking
physicians’ or cardiologists’ opinion. 4.2 Medical staff should receive a copy of this policy as part of their local induction. 5. IMPORTANT NOTE
At all times this policy should be used in conjunction with the latest SPC (manufacturer’s Summary of Product Characteristics or Datasheet), the latest Trust Guidelines, the latest NICE publications, the current Maudsley Guidelines, MHRA alerts, NPSA alerts, current BNF/eBNF and other relevant publications. If in doubt seek expert opinion.
9 Electrocardiograph (ECG) Policy Version: 1 January 2017
6. MONITORING The implementation of this policy will be monitored as part of the annual physical
healthcare audits undertaken by service directorates. This will be the responsibility of the Clinical Governance leads of each directorate.
7. ASSOCIATED DOCUMENTS
SH CP 134 - Guidelines for the use of High Dose Antipsychotics
SH CP 113 - Shared Care Guidelines for Prescribing Lithium
SH CP 46 - Electro Convulsive Therapy Policy
SH CP 17 - Zuclopenthixol Acetate Guidelines
SH CP 48 - Rapid Tranquillisation: Policy and Guidance for use in Mentally Ill Patients Displaying Acutely Disturbed or Violent Behaviour
SH CP 114 - Clozapine Guidelines
SH CP 44 - Physical Assessment and Monitoring Procedure for Integrated Community Services
SH CP 45 - Physical Assessment and Monitoring Procedure for Mental Health and Learning Disability Services
Current Summary of Product Characteristics (data sheet) www.emc.medicines.org.uk
SH CP 40 - Medical Devices Management Policy
Psychotropic Drug Directory 2009 by Stephen Bazirre. Published by HealthComm UK Ltd. Chapter 3.2 Cardiovascular disease p248 – 259.
British National Formulary no.71, March 2016
The Maudsley Prescribing Guidelines 12th edition by Taylor, Paton & Kapur.
HPFT Substance Misuse Services: ECG Assessment and Monitoring
SH CP149 - Physical health monitoring guideline for medicines commonly prescribed in mental health
QT interval and drug therapy. Drug and Therapeutics Bulletin. Vol 54 (3) p33-36. March 2016
Appendix 1
10 Electrocardiograph (ECG) Policy Version: 1 January 2017
Psychotropic medication effects on QTc interval (based on the Maudsley Guidelines 12th Edition)
1 No Effect 3 Moderate Effect
Aripiprazole Lurasidone
Reboxetine Mirtazapine MAOIs
Carbamazepine Gabapentin Lamotrigine Valproate
Benzodiazepines
Amisulpride** Chlorpromazine Haloperidol Iloperidone Levomepromazine Melperone Quetiapine Ziprasidone
Citalopram/ Escitalopram/ Fluoxetine Tricyclics antidepressants Lofepramine
4 High Effect
Any IntraVenous Antipsychotic Pimozide Sertindole Thioridazine
Any drug or combination of drugs used if exceeding recommended maximum. (see High Dose Antipsychotic Policy)
2 Low Effect
Asenapine Clozapine Flupentixol Fluphenazine Perphenazine Prochlorperazine Olanzapine* Paliperidone Risperidone Sulpiride
Bupropion Moclobemide Venlafaxine Trazodone
Lithium
Unknown Effects
Loxapine Pipothiazine Trifluoperazine Zuclopenthixol
Anticholinergic drugs (Procyclidine, Benzhexol etc.)
Zuclopenthixol Acetate (Acuphase®) – see Trust Policy
1. No effect drugs are those in which QTc prolongation has not been reported either at therapeutic doses or in
overdose. 2. Low effect drugs are those for which severe QTc prolongation has been reported only following overdose or
where small increases have been observed at clinical doses. 3. Moderate effect drugs are those that have been observed to prolong QTc by more than 10 milliseconds on
average when given a normal clinical dose or where ECG monitoring is officially recommended in some circumstances.
4. High effect drugs are those for which extensive average QTc prolongation is usually greater than 20 milliseconds at normal clinical doses has been noted and where ECG monitoring is mandated by the manufacturers data sheet (SPC). * isolated cases of QTc prolongation & has effects on cardiac ion channel,IKR, other data suggests no effect on QTc **Torsade de pointes common in overdose
However the effect on QTc may not necessarily equate directly to risk of torsades de pointes or sudden death
Appendix 1
11 Electrocardiograph (ECG) Policy Version: 1 January 2017
Concurrent drug use: Non psychotropics associated with QT prolongation (see current BNF for complete list)
Antibiotics Antiarrhythmic
Erythromycin Clarithromycin Ampicillin Co-trimoxazole Pentamidine Some 4-Quinolones (see SPC)
Quinidine Disopyramide Dronedarone Flecainide Procainamide Sotalol Amiodarone Bretylium
Antimalarials Others
Chloroquine Mefloquine Quinine
Amantadine Antifungals (fluconazole, ketoconazole) Antiretrovirals eg foscarnit Ciclosporin Cisapride Antimotility & Antiemetic (domperidone, granisetron, ondansetron) Diphenhydramine Hydroxyzine Methadone** Protein kinase inhibitors e.g. Sorafenib, Sunitinib Nicardipine Tamoxifen
* not in 10th or 11th edition of Maudsley guidelines but added due to recent alerts ** was previously listed (in 10th ed) under psychotropic drugs, now listed under non-psychotropic drugs (11th ed Maudsley)
Appendix 2
12 Electrocardiograph (ECG) Policy Version: 1 January 2017
CONFIDENTIAL
Cardiology Department, Queen Alexandra Hospital, Portsmouth, PO6 3LY ECG FAX BACK SERVICE
Instructions to referring Doctor: 1. Please identify each faxed page with the patient’s name. 2. Fax the fully completed form and recent 12 Lead ECG to 02392 286092 3. Note that this is NOT a referral and the Cardiologists will merely fax back a report Date: ________________________ Patient Details: Name: ___________________ D.O.B _____________________ NHS Number ___________________ Gender: ___________________ Ethnicity: _____________________ Reason for ECG, Relevant Medication & Known Cardiac History (Brief Summary) To Whom should the Fax Report be sent: Drs Name: _______________________ Fax No:_________________ Drs Tel No:_______________________ Consultant Report: Recommendations: Name: ____________________________ Date: ___________________
Appendix 3
13 Electrocardiograph (ECG) Policy Version: 1 January 2017
ECG Fax Back Service
Parties to the Agreement: Supplier: Portsmouth Hospitals NHS Trust Customer: Southern Health NHS Foundation Trust Purpose: This agreement represents a contract between Portsmouth Hospitals
NHS Trust and Southern Health NHS Foundation Trust for the provision of an ECG Fax Back service for routine ECG reports faxed in by Adult, Old Age, Specialised Services and Learning Disabilities Psychiatrists employed by Southern Health NHS Foundation Trust.
The Service: Service Principles: The service principle is to provide timely and accurate specialist cardiological interpretation and advice in relation to 12 lead ECG reports. Service Aims and Objectives: The service aims to provide timely interpretation of ECG reports, to include identification of any noteworthy anomalies and recommended resulting actions where appropriate. Service Specification: HPFT will ensure that:
Staff use the agreed ECG fax back service form, ensuring that each faxed page includes the patient name and that all details are completed as outlined on the form, including details of referrer, secure fax number and telephone number for a response.
PHT will undertake to:
Ensure a cardiological opinion (i.e. consultant cardiologist or cardiology registrar) is obtained for all ECG reports faxed to the service and that a response is faxed back to the requesting Doctor within 2 working days of receipt. The Faxback will include interpretation and recommended actions where appropriate. The timeframe for response is conditional on the appropriate form being fully completed.
Locations Served: All Southern Health NHS Foundation Trust services
Appendix 3
14 Electrocardiograph (ECG) Policy Version: 1 January 2017
Normal Working Hours: The Department is open Monday – Friday 9.00am – 4.30pm. ECG reports can be faxed outside these times and will be dealt with within 2 working days (excludes Saturday and Sunday). Activity Levels: Activity levels have been estimated at roughly 300 fax back requests per year. Service Charges: Cost per ECG faxback is £10.00 Invoice details will need to include details of referrer, team/unit base and relevant Directorate Monitoring Arrangements: Initial review meeting at six months to review the following:
Activity to include referrer and team/unit base as per those on invoice details
Fax-back return times
Common anomalies identified on ECG reports, including frequency of poor quality ECG reports being received
Following this initial meeting, review meetings to occur on an annual basis.
Appendix 4
15 Electocardiograph (ECG) Policy Version: 2 August 2016
ECG EASY GUIDE
Patient admitted to ward
Normal ECG
(QTc <440ms men <470ms women)
No acute action needed
Repeat prior to discharge, then
follow guidelines for outpatient
management If on clozapine will need ECG after 3 and 6 months then
annually If on high-dose
antipsychotics refer to policy
Perform ECG
Where possible prior to starting psychotropics In conjunction with physical examination and blood tests
Abnormal
QTc
Abnormal T-wave
morphology
Other abnormality
on ECG
QTc > 440ms men
or > 470ms women
but <500ms
Consider reducing dose or switching to drug
of lower effect Repeat ECG and consider referral to cardiologist
QTc >500ms
Stop causative drug(s) and
switch to drug of lower effect,
refer to cardiologist immediately
Review treatment.
Consider
reducing dose or switching to drug of lower
effect. Refer to cardiologist immediately
Treat any urgent abnormality.
Seek specialist advice.
Patient is unable to have an ECG, attempt physical
monitoring (HR, BP, T, RR) & retry ECG as soon
as possible. Record.
16 Electocardiograph (ECG) Policy Version: 2 August 2016
Appendix 5 Training Needs Analysis
If there are any training implications in your policy, please complete the form below and make an appointment with the LEaD department (Louise Hartland, Quality, Governance and Compliance Manager or Sharon Gomez, Essential Training Lead on 02380 874091) before the policy goes through the Trust policy approval process.
Training Programme
Frequency Course Length Delivery Method Facilitators Recording Attendance Strategic & Operational
Responsibility
E- learning
Once
30- 45 minutes E- Learning online Via MLE
Operational responsibility Dr Mary Kloer, Consultant Psychiatrist Strategic Responsibility Julie Dawes Director of nursing
Directorate Service Target Audience
MH/LD/TQ21
Adult Mental Health
All staff required to perform an ECG as part of their role
Specialised Services
All staff required to perform an ECG as part of their role
Learning Disabilities
All staff required to perform an ECG as part of their role
TQtwentyone
Not applicable
ISD’s
Older Persons Mental Health
All staff required to perform an ECG as part of their role
ISD’s
Adults
All staff required to perform an ECG as part of their role
ISD’s
Childrens Services
Not applicable
Corporate
All
Not applicable
17 Electocardiograph (ECG) Policy Version: 2 August 2016
Appendix 6 Equality Analysis Form
The Equality Analysis is a written record that demonstrates that you have shown due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations with respect to the characteristics protected by the Equality Act 2010. Stage 1: Screening
Name of policy/procedure Electrocardiograph (ECG) Policy
Name and job title of person
completing the assessment:
Ricky Somal: Equality and Diversity Lead
Date of assessment: April 2016
Responsible department:
Intended equality outcomes: The aim of the ECG policy is to provide pragmatic advice as to what is best practice and inform clinicians of potential cardiac risks to patients treated in mental health services. The Trust is implementing the EDS2 which allows a robust examination of Trust performance on Equality, Diversity and Human Rights. This is based on equality key objectives that include:
1. Better health outcomes for all
2. Improved patient access and experience
3. Empowered, engaged and included staff
4. Inclusive leadership
JSNA 2015
Good life expectancy for both men and women that compares well to
our CIPFA neighbours. Life expectancy has increased by 3.2 years
for men (to 81.1 years) and 2.3 years for women (to 84.2 years) from
2000/02 to 2011/13
Fewer people dying from conditions that could be avoided comparing
very well to our CIPFA neighbours
Fewer children living in poverty and less infant mortality comparing
well to our CIPFA neighbours
Good overall educational attainment particularly in the early years
Less long-term unemployment compared to national and regional
rates
Who was involved in the
consultation of this
document?
Please describe the positive and any potential negative impact of the policy on service users or staff. In the case of negative impact, please indicate any measures planned to mitigate against this by completing stage 2. Supporting Information can be found be following the link: www.legislation.gov.uk/ukpga/2010/15/contents
18 Electrocardiograph (ECG) Policy Version: 1 January 2017
Protected
Characteristic
Positive Impact Negative Impact
Age The population of Hampshire is changing; our population is getting older and we are becoming more diverse:
The population of Hampshire is estimated
to be 1.34 million people, making it the
third most populous county in England
after Kent and Essex.
Young people (aged 0-19) make up 23%
of the population compared to 24%
nationally.
Hampshire has fewer young working aged
people (aged 20-39) compared to England
as a whole; 23% in Hampshire compared
to 27% in England.
Older people (over the age of 75) make up
10% of the population compared to 8%
nationally.
No adverse impacts identified at this
stage of screening
Disability For people with mental health problems
and learning difficulties, additional time is
given to communicate effectively with the
patients to create better understanding of
what the tests involve.
Southern Health aims to ensure service
are designed to meet the health needs of
the local community and offers
interpreting and translation services.
No adverse impacts identified at this
stage of screening
Gender
reassignment
Individual patients’ health needs are
assessed, and resulting services
provided, in appropriate and effective
ways
No adverse impacts identified at this
stage of screening
Marriage & civil
partnership
Individual patients’ health needs are
assessed, and resulting services
provided, in appropriate and effective
ways
No adverse impacts identified at this
stage of screening
Pregnancy &
maternity
Individual patients’ health needs are
assessed, and resulting services
provided, in appropriate and effective
ways
No adverse impacts identified at this
stage of screening
Race Southern Health aims to ensure service
are designed to meet the health needs of
the local community and offers interpreting
and translation services.
The ethnic diversity in Hampshire is much
lower than England as a whole (8.2%
compared to 20.2% respectively) but it is
No adverse impacts identified at this
stage of screening
19 Electrocardiograph (ECG) Policy Version: 1 January 2017
gradually increasing across the county.
While the population remains
predominantly white British, the proportion
of the population that is of ethnic origin
has increased from 4.6% in 2001 to 8.2%
in 2011
Asian ethnic groups make up the largest
non-white categories in Hampshire.
Rushmoor has the largest non-white
population at 15.3% (up from 4.4% in
2001); mostly due to a growing Nepalese
population.
Religion/Belief Individual patients’ health needs are
assessed, and resulting services
provided, in appropriate and effective
ways
No adverse impacts identified at this
stage of screening
Sex Life expectancy for men in Hampshire has
risen from 77.9 years in 2000-02 to 81.1
years in 2011-13 and is significantly
better than the male life expectancy for
England.
Life expectancy for women in Hampshire
has increased from 81.9 years in 2000-02
to 84.2 years in 2011-13 and is
significantly better than female life
expectancy for England
No adverse impacts identified at this
stage of screening
Sexual
orientation
Individual patients’ health needs are
assessed, and resulting services
provided, in appropriate and effective
ways
No adverse impacts identified at this
stage of screening
Stage 2: Full impact assessment
What is the impact? Mitigating actions Monitoring of actions